

Thursday, February 12, 2026

Keynote

12:30 - 13:15

Plenary

KN1 - Opening and Keynote Lecture 1

OP

Opening

12:30 - 12:45

Annalisa Ruggeri (Milan, Italy)
Maria Themeli (Amsterdam, Netherlands)

KN1

Keynote Lecture

12:45 - 13:15

Dirk Busch (Munich, Germany)

Physicians Session

13:30 - 15:00

Plenary

PS1 - Acute Leukaemia

Julio Delgado (Barcelona, Spain)
Fabio Ciceri (Milano, Italy)

PS1-1

Paediatric ALL

13:30 - 13:45

Franco Locatelli (Rome, Italy, Italy)

PS1-2

Adult ALL and toxicity prediction models

13:45 - 14:00

Jordan Gauthier (Seattle, United States)

PS1-3

T-ALL

14:00 - 14:15

Nicola Maciocia (London, United Kingdom)

PS1-4

AML

14:15 - 14:30

Marion Subklewe (Munich, Germany)

PS1-5

Discussion

14:30 - 15:00

Break

15:00 - 15:40

IT

Coffee Break

Industry Theatre

15:05 - 15:25

IT

IT01 - Industry Theatre / Tech Talk 1

Physicians Session

15:40 - 17:10

Plenary

PS2 - Translational Session I: New frontiers and innovations

Maria Themeli (Amsterdam, Netherlands)
Chiara Bonini (MILAN, Italy)

PS2-1

Keynote Lecture

15:40 - 16:05

Carl June (Philadelphia, United States)

PS2-2

AI use for CAR design

16:05 - 16:25

Andrea Schmidts (Munich, Germany)

PS2-3

Multiplex genetic engineering of immune cells

16:25 - 16:45

Sidi Chen (New Haven, United States)

PS2-4

AI-driven engineered T cell therapies for cancer and autoimmune diseases

16:45 - 17:05

Zinaida Good (Stanford, California, United States)

Conclusions

17:05 - 17:10

Bite Symposium

17:25 - 18:10

Plenary

SS01 - Satellite Symposium by Bristol Myers Squibb*Physicians Session*

18:20 - 19:50

Plenary

PS3 - Patient in focus: Delving into CAR-T cell therapy accessibility challenges

Natacha Bolaños (Madrid, Spain)

Solène Clavreul (Nantes, France)

PS3-1	Introduction & framing Solène Clavreul (Nantes, France) Natacha Bolaños (Madrid, Spain)	18:20 - 18:40
PS3-2	Health System & Registry Perspective Christian Chabannon (Marseille, France)	18:40 - 19:00
PS3-3	Policy & Affordability Perspective	19:00 - 19:20
PS3-4	Panel discussion & Audience Q&A	19:20 - 19:50

Meet-the-Experts

18:30 - 19:00

Nurses

MTE - Meet the Experts*Poster Session*

19:55 - 20:55

IT

Welcome Reception & Poster Session

Chimeric Antigen Receptor T Cells Generated from Tissue-homing T Cells to Treat Solid Tumors Eva Pascal (Ghent, Belgium)	19:55 - 19:55
Prognostic Factors of CAR T Response in Patients with Relapsed or Refractory B-cell Lymphoid Malignancies: A Single Institution Analysis Soo Jung Lee (Suwon, Korea, Republic of)	19:55 - 19:55
Persistent Lymphocytosis after Anti-BCMA CAR-T Infusion in a Patient with MMRR	19:55 - 19:55
Engineering Human RBP4-based Molecular Switches for Functional Control of CARs and Transcription Factors Manfred Lehner (Vienna, Austria)	19:55 - 19:55
Optimizing CAR-T Expansion Conditions for the First Polish Academic Multiple Myeloma Therapy	19:55 - 19:55
A Not too Broken Heart - Axixel for Relapsed Diffuse Large B-cell Lymphoma (DLBCL) with a Background of Dilated Cardiomyopathy Gillian Flynn (Southampton, United Kingdom)	19:55 - 19:55
Guillan-Barré-like Syndrome in a Patient Receiving Cilta-cel in Relapsed/Refractory Multiple Myeloma	19:55 - 19:55
Feasibility and Impact of Tailored Bridging Therapy for CAR-T Therapy in Relapsed/Refractory Multiple Myeloma	19:55 - 19:55
CD19-negative Relapse and Treatment-related Mortality after Tisagenlecleucel in B-lymphoblastic Leukemia: A Case Report Chi Yen Chen (Taichung City, Taiwan)	19:55 - 19:55
Novel CAR-based Cellular Therapy Targeting Membrane-bound	19:55 - 19:55

Immunoglobulin E

Alicja Wojciechowska (Warsaw, Poland)

Sustained Remission of Acquired Hemophilia A with a CD3xBCMA-directed Bispecific Antibody after Failure of Second Anti-CD19 CAR-T Cell Therapy 19:55 - 19:55

A Comparison of the Efficacy and Toxicity of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Patients with Large B-cell Lymphoma: A Retrospective, Single-centre Analysis 19:55 - 19:55

Tonia Comino (Zurich, Switzerland)

A Case of Dual Malignancy - High Risk Multiple Myeloma with Multiple Relapses and Prostate Adenocarcinoma and Trying of CAR-T Based Therapy + Hormone Therapy 19:55 - 19:55

Baishnav Suresh (Bhubaneswar, India)

Development of a Point-of-Care Manufacturing Facility at an Academic Center in Türkiye: Validation Study for Anti-CD19 CAR-T Cells Using a Closed Cell Processing Platform 19:55 - 19:55

Fatma Visal Okur (Ankara, Turkey)

Rapid Manufacture and Effective Response of FIT-CD19 CAR-T in Relapsed B-ALL: A Case from NTUH 19:55 - 19:55

First Treatment with the Fully Human MUW-huCD19.1 CAR-T Cell Therapy for Diffuse Cutaneous Systemic Sclerosis 19:55 - 19:55

T and NK Cells on the Move: A Side-by-Side Comparison of Migration Dynamics and Cytotoxic Potential of Naive and Genetically Engineered T and NK Cells 19:55 - 19:55

Alina Moter (Frankfurt am Main, Germany)

Access to CAR-T Cell Therapy across ALL-IC Relapse Study Group Countries: Results from an International Survey 19:55 - 19:55

Koray Yalcin (İstanbul, Turkey)

Novel Proximity-labelling Approach to Investigate CAR-based Immune Synapse 19:55 - 19:55

Engineering of Immunological Synapse through Novel Integrin-based Activation Receptor (IBAR) 19:55 - 19:55

Harnessing the Extracellular Matrix to Boost CAR-T Cell Therapy in Solid Tumors 19:55 - 19:55

In vivo Expansion and Persistence of CD33- and CD123-directed Allogeneic CAR-T Cells in Pediatric Relapsed/Refractory AML after HSCT: A Single-center Experience from Russia 19:55 - 19:55

Andrey Russiyanov (Moscow, Russian Federation)

Combinatorial Strategy for Improved CDH17-CAR T Cell Therapy of Liver Metastases from Colorectal Cancer 19:55 - 19:55

Katia Palmisano (Milan, Italy)

Place-of-Care Produced Fresh Formulation CD19 CAR-T Cell Therapy in Patients with BTKi-exposed Relapsed or Refractory CD19+ Mantle Cell Lymphoma 19:55 - 19:55

Skirmante Cernauskiene (Vilnius, Lithuania)

When Remission Is Not Enough: Non-relapse Morbidity after CAR T-cell Therapy 19:55 - 19:55

Rational Engineering of sdAb-based CAR-T Cells Targeting BCMA Enhances Efficacy and Persistence in Preclinical Models of Multiple Myeloma 19:55 - 19:55

Juan Roberto Rodriguez-Madoz (Pamplona, Spain)

Translational Development of CD70-directed NanoCAR T-cells for Clear Cell Renal Cell Carcinoma: Efficacy, Safety and Innovation 19:55 - 19:55
Robrecht De Vos (Ghent, Belgium)

“Real World” Incidence and Characteristics of Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis: A GoCart Coalition Study on behalf of the EBMT ADWP, CTIWP and TCWP 19:55 - 19:55

A Tale of llamas and CARs: V_HH-based CLEC12A-CAR NK Cells for the Treatment of Acute Myeloid Leukaemia 19:55 - 19:55

Tyrosine Kinase Inhibitor Therapy Does Not Impair the Quality of Anti-CD19 CAR-T Cell Product 19:55 - 19:55

Relationship between CAR Spatial Organization and CAR-T Cell Function Revealed by Imaging Flow Cytometry and Transcriptomic Profiling 19:55 - 19:55
Gianluca Rotta (Milan, Italy)

In-vivo Dynamics of a Novel CD19-directed CAR-T Cell Therapy in Paediatric and Young Adults with Relapsed/Refractory B-acute Lymphoblastic Leukemia (R/R B-ALL) 19:55 - 19:55
Aafreen Ansari (Mumbai, India)

Restoring Mitochondrial Metabolism of iPSC-derived CAR/TCR-T Cells Improves their Anti-tumor Efficacy 19:55 - 19:55

Long-term Progression-free Survival Benefit with Ciltacabtagene Autoleucel in Standard-risk Relapsed/Refractory Multiple Myeloma 19:55 - 19:55
Paula Rodríguez-Otero (Pamplona, Spain)

Polymer-based Vectors for Plasmid Delivery: Early Development of a New Non-viral CAR-T Approach 19:55 - 19:55
Sofia Zuffi (Donostia-San Sebastian, Spain)

Early Single-center Experience in the Treatment of Pediatric T-ALL with Unedited Allogeneic Anti-CD5 CAR-T Cells Manufactured at the Point of Care in Combination with Allo-HSCT 19:55 - 19:55

A multicentre Analysis of CAR-T Cell Toxicities, Target Antigens and Dosing in Solid and Haematological Malignancies 19:55 - 19:55

Estimating the Real Price of CAR T-cells in France: From List Price to Net Price 19:55 - 19:55

Redirected Killing of Allergen-specific CD4⁺ T Cells by pHLA Class II CAR NK-92 Cells 19:55 - 19:55
Isidora Protic Rosic (Vienna, Austria)

Structure-guided Tuning of a Trastuzumab-based Chimeric Antigen Receptor Enables Tumor-Selective Targeting with Improved Safety and Preserved Efficacy for HER2-positive Breast Cancer 19:55 - 19:55
Maria Lysandrou (Groningen, Netherlands)

An Indigenous CAR-T Journey: Managing IEC-HS and Tracking Response Using a Homegrown CTDNA Assay 19:55 - 19:55
Anusha Swaminathan (Gurugram, India)

JOIN4ATMP: Mapping the European Clinical Trial Landscape of Advanced Therapy Medicinal Products (ATMPs) 19:55 - 19:55
Stephanie Winter (Vienna, Austria)

Prognostic Utility of PET Imaging Parameters in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Undergoing 19:55 - 19:55

CAR-T Cell Immunotherapy: A Retrospective Single-center Analysis

Livia Donzelli (Rome, Italy)

Searching for the Ideal CAR-T Target in AML: Balancing Expression and Toxicity

Florian Van Oers (Wilrijk, Belgium)

Eosinophilia as a Novel Biomarker of Toxicity and Response in LBCL Patients Treated with CD19 CAR T-cell Therapy**Early Experience with T-cell Receptor Cellular Therapy in Advanced Solid Malignancies: A Multi-centre Analysis of Safety and Efficacy****Developing B7H3-STAR-T Cells to Increase Antigen Sensitivity and Circumvent Tumor Escape by Antigen Downregulation****Optimisation of CAR-T Therapy Treatment in Ambulatory Care: Is it Feasible?****Systemic Barriers to CAR-T Access: Insights from a Certified German Center - First Results from the EASYGEN Consortium**

Dominik Narres (Bad Homburg, Germany)

Early Follow-up of the First Czech Real-world Data Analysis of Brexucabtagene Autoleucel in the Treatment of Acute Lymphoblastic Leukemia**Varnimcabtagene Autoleucel (ARI-0001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Retrospective Study****Adjuvant-backpacked CAR T Cells: CAR-T Cells Equipped with Poly I:C-nanoparticles to Reprogram M2c Immunosuppressive Macrophages and Remodel the Tumor Microenvironment****Exploiting Microbiota to Improve CARCIK Cell Fitness and Metabolism for the Treatment of Acute Myeloid Leukemia**

Orsola Montini (Monza, Italy)

Interprofessional Simulation-based Training to Enhance Toxicity Recognition and Management during CAR T-cell Service Implementation in Ireland

Deirdre Moloney (Galway, Ireland)

Boosting CAR T-cell Therapy in Multiple Myeloma Combining *in silico* Perturbation Predictions and Drug Repurposing

Alessia Buratin (Barcelona, Spain)

Pharmacist Medication Review for Patients Preparing for Chimeric Antigen Receptor T-cell Therapy - A Service Evaluation**Transverse Myelitis as a Rare Non-ICANS Neurotoxicity Following CAR T-Cell Therapy****Clinical Experience in Sleeping Beauty Transposon-based CAR-T-Cell Manufacturing****Optimizing Tocilizumab Dosing in CAR-T-associated Cytokine Release Syndrome: When Less Is Enough****Reprogramming the Tumor Microenvironment: A CAR-T and CAR-macrophage Dual Approach for Solid Cancers****Combining CAR-modified Immune Cells to Overcome Cancer Resistance in Solid Tumors**

Co-expressing a Conventional and an Adapter CAR Allows for Multi-antigen Targeting in Heterogeneous Multiple Myeloma	19:55 - 19:55
Modeling of Metastatic Neuroblastoma in Syngeneic Immunocompetent Mice to Guide Engineering of CAR T Cells	19:55 - 19:55
Generation of a Dual-fluorescent NK-cell Reporter System to Monitor CAR-NK Activation and Inhibition	19:55 - 19:55
High-resolution Longitudinal Immune Cell Profiling Reveals Distinct Cellular Patterns Linked to Prolonged Cytopenia after CAR T-cell Therapy	19:55 - 19:55
Cesnicabtagene Autoleucel (ARI0002H) in Patients with Ultra-high Risk Multiple Myeloma	19:55 - 19:55
Acute Kidney Injury in Patients with Multiple Myeloma Receiving Cesnicabtagene Autoleucel (ARI0002h)	19:55 - 19:55
In Splenectomized Patients with B-cell Malignancies, CAR-T Cell Therapy Is Well-tolerated and Associated with Low Incidence of Severe Infections	19:55 - 19:55
GXMR-CAR T Cell Activation Enhanced by Costimulatory Domain in Response to <i>Cryptococcus</i> spp Milena Barrocali Araújo MELO (Araraquara, Brazil)	19:55 - 19:55
Targeting CD133 with Single-domain Antibody-based CAR T Cells to Treat Solid Tumors	19:55 - 19:55
ST2 as a Biomarker of Cytokine Release Syndrome Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy	19:55 - 19:55
CAR-FIT: CAR-T Fitness Index — Integrating Comorbidity and Geriatric Assessments to Guide Safe and Equitable Delivery of CAR-T in Patients with Borderline Physiological Reserve	19:55 - 19:55
The Cost Savings Potentials of Virtual Twins for Personalised CAR T-cell Therapy in Multiple Myeloma Marija Radic (Leipzig, Germany)	19:55 - 19:55
Development of Nectin-2 Specific Nano-CARs for the Treatment of Melanoma Carolin Birr (Bonn, Germany)	19:55 - 19:55
Global Brexucabtagene Autoleucel (Brexu-cel) Manufacturing Experience for Adult Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) or Mantle Cell Lymphoma (MCL)	19:55 - 19:55
iMMagine-3: Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel with Standard of Care in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	19:55 - 19:55
Exploring Bone-marrow TILs as an Alternative T-cell Source for CAR-T Therapy in AML	19:55 - 19:55
Immune Cell Profiling in Lymphoma Patients Treated with CAR-T Cell Therapy and Nivolumab	19:55 - 19:55
CD37 Is a Promising Molecular Target for CAR-T Cells in Chronic Lymphocytic Leukemia	19:55 - 19:55
Late Parvovirus B19 Reactivation Causing Severe Cytopenias after CD19-directed CAR-T Therapy for Diffuse Large B-cell Lymphoma: A Case Report	19:55 - 19:55

Reinforcing Anti-BCMA CAR T-cells in t(11;14) Multiple Myeloma	19:55 - 19:55
CD4⁺/CD8⁺ CAR⁺ T-cell Ratio at Peak Expansion Predicts Clinical Outcomes Following CAR-T Cell Therapy	19:55 - 19:55
Chronic Exposure to CAR-T Secretome Depletes Human Hematopoietic Stem Cells via TNFα/IFNγ-BATF2 Signaling Axis, Reversible by cAMP Pathway Activation	19:55 - 19:55
Oral Health of Lymphoma Patients Treated with Car-T Cells	19:55 - 19:55
The Experiences of Adult Cancer Patients Receiving Chimeric Antigen Receptor T-cell (CAR-T) Therapy: A Scoping Review Isabela Girleanu (Dublin, Ireland)	19:55 - 19:55
Novel MHC Multimer Technology for Sensitive Discovery, Analysis, and Enrichment of Antigen-specific T Cells to Advance TCR-based Cancer Immunotherapies Nicholas Tokarew (Bergisch Gladbach, Germany)	19:55 - 19:55
Functional Properties of CD4⁺ and CD8⁺ CAR T Cells: Can Extreme CD4/CD8 Ratios Impact Release Testing? Nicholas Tokarew (Bergisch Gladbach, Germany)	19:55 - 19:55
Endogenous T Cell Reprogramming in CAR T Cell Therapy-associated Toxicities in B Cell Lymphoma Patients Stefanie Kreutmair (Zurich, Switzerland)	19:55 - 19:55
Impact of CAR-T Cell Product Characteristics and Persistence on Clinical Outcomes of Allogeneic Cocktail CD19 and CD22 CAR-T Therapy Following PtCy-based allo-HSCT in Pediatric ALL	19:55 - 19:55
Impact of Bridging Response on CAR-T Outcomes in High-risk B-cell Malignancies: A Four-case Real-world Experience	19:55 - 19:55
Artificial Targets for Functional Characterization of CAR T Cells Nadine Borgelt (Bergisch Gladbach, Germany)	19:55 - 19:55
Monitoring and Clearance of Circulating Plasma Cells (CPCs) in Myeloma Patients Undergoing CAR-T Therapy Ilaria Vigliotta (Bologna, Italy)	19:55 - 19:55
Impact of Chimeric Antigen Receptor (CAR) Product Cell Phenotypes on Clinical Outcomes Following Treatment with Obecabtagene Autoleucel (Obe-cel)	19:55 - 19:55
CD19 Antigen: From Tumor Target to Safety Switch Able to Improve the Safety Profile of CAR T Cell Therapy Simona Manni (Roma, Italy)	19:55 - 19:55
Long-term Neurological and Psychiatric Outcomes after CD19 and BCMA Chimeric Antigen Receptor T-cell (CAR-T) Therapy: A Retrospective Analysis of Real-world Data from over 2200 Patients Katharine Lynch-Kelly (London, United Kingdom)	19:55 - 19:55
Risk Factors to Determinate Tisagenlecleucel Treatment Efficacy in Patients with NHL - Single Center Experience	19:55 - 19:55
Histopathological Predictors of Outcome in CD19 CAR-T Therapy for Diffuse Large B-cell Lymphoma: A National Real-world Cohort Study	19:55 - 19:55
CAR-T Timing Matters: Better Immune Fitness with Second-line Axicabtagene Ciloleucel in Relapsed/Refractory Large B-cell Lymphomas	19:55 - 19:55

Effect of Various Plant Extracts on CAR-T Cell Immunophenotype and Viability	19:55 - 19:55
CAR T-cell Therapy in Austria 2024: Demand and Access Challenges	19:55 - 19:55
Smoking and Coronary Artery Calcification as Predictors of ICANS in Anti-CD19 CAR T-Cell Therapy for the Treatment of Patients with LBCL Tatum N. Storck (Groningen, Netherlands)	19:55 - 19:55
A Spheroid Model to Cultivate Multiple Myeloma Cells in a Stromal/Collagen-based 3D Scaffold and Assess Anti-BCMA CAR-T Cells Activity	19:55 - 19:55
Real-world Outcomes of Adult Patients with Triple-class Exposed Relapsed or Refractory Multiple Myeloma: Evidence from a Multicenter Retrospective Study (MMIRROR-1)	19:55 - 19:55
Real-world Data of CAR T Therapy in Large B-cell Lymphoma - Outcomes from the First 100 Patients Treated in Ireland	19:55 - 19:55
Timing of G-CSF Use during Cytokine Release Syndrome Following CD19 CAR T-cell Therapy in Refractory Ph-like B-ALL: A Clinical Learning Experience	19:55 - 19:55
Rationale for the T2EVOLVE Pilot Project to Use a New Patient-centred Format for the Informed Consent Form in a German Multicentre Phase-I CAR T-cell Study Barbara Huber (Würzburg, Germany)	19:55 - 19:55
Severe Case of ICANS in Patient with Classic Follicular Lymphoma Treated with Tisagenlecleucel after Bridging Therapy with Mosunetuzumab	19:55 - 19:55
CCL8⁺CCL13⁺ Tumor-associated Macrophages Drive Early Resistance to CAR T-cell Therapy in Large B-cell Lymphoma	19:55 - 19:55
Transduction Efficiency Comparison of mRNA Carrier Lentivirus-like Particles Manufactured via Different Lentiviral Packaging Systems	19:55 - 19:55
ApoE-DARPin Fusion Proteins Enable Cell-specific mRNA Delivery by Lipid Nanoparticles	19:55 - 19:55
A Protein Engineering Strategy to Generate Novel Anti-CD72 Ligands for a CAR-T Approach to Pediatric AML and B-ALL	19:55 - 19:55
Efficient and Rapid Generation of CAR-T Cells in GMP-scalable Devices Sara Boscarato (Padova, Italy)	19:55 - 19:55
Etoposide as an Effective Rescue Treatment for Severe IEC-HS after CAR-T Cell Treatment for Progressive Multiple Myeloma	19:55 - 19:55
B7-H3-Directed CAR T Cells as a Promising Therapeutic Strategy for Acute Myeloid Leukemia Pamela De Falco (Rome, Italy)	19:55 - 19:55
Respiratory Complications in CAR T-cell Therapy Recipients: Insights from a Single UK Centre Emily John (London, United Kingdom)	19:55 - 19:55
A New Deep Learning Model for the Automatic Recognition of Lymphocyte Differential during the Hematopoietic Recovery after CAR-T Therapy José Rodellar (Barcelona, Spain)	19:55 - 19:55

Understanding the Mechanistic Role of the Intestinal Microbiome on CAR T Cell Therapy Outcomes in a Preclinical Mouse Model	19:55 - 19:55
Peptide-mediated Delivery of Gene-editing Tools for Efficient Engineering of Primary Human T Cells	19:55 - 19:55
Engineering Caffeine-responsive Molecular Switches to Control CAR T Cell Function <i>in vivo</i> Michael W. Traxlmayr (Vienna, Austria)	19:55 - 19:55
Application of the CAR-hematotox Score in Patients Undergoing Anti-CD19 CAR-T Cell Therapy at the University Hospital Complex of A Coruña	19:55 - 19:55
Impact of Polatuzumab Vedotin as Bridging Therapy in Relapsed or Refractory Aggressive B-cell Lymphomas: Single-center Experience with Axicabtagene Ciloleucel (Yescarta®)	19:55 - 19:55
Impact of Prior Antibiotic Exposure on the Outcomes of Bispecific Antibodies in Non-Hodgkin B-cell Lymphomas: A Real-world Retrospective Study	19:55 - 19:55
Engineering and Optimization of Non-viral Nanocarriers for CAR-T Cell Manufacturing Alberto Jimenez Lomo (Santiago de Compostela, Spain)	19:55 - 19:55
Co-designed CAR T-cell Therapy Education: Launching a CPD-accredited E-learning Resource for Healthcare Professionals Emily John (London, United Kingdom)	19:55 - 19:55
Unmasking Mechanisms of TME-driven CAR-T Cell Dysfunction in Solid Tumors Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	19:55 - 19:55
Uncovering Key Regulators of CAR-T Cell Senescence via Integrated CRISPR Screens and Immune Phenotyping Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	19:55 - 19:55
Molecular Characterization of Extraordinary Long-persistent CAR-T Cells in a R/R MM Patient Treated with Academic BCMA-targeting CAR-T Therapy Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	19:55 - 19:55
Novel HER2-specific sdAb-based CAR-T Cells Exhibit Enhanced Antitumoral Efficacy in HER2-positive Cancers Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	19:55 - 19:55
Establishing a Nurse-led Solid Tumour Cell Therapy Clinic for Patients on Clinical Trials Including a Preliminary Evaluation	19:55 - 19:55
Place-of-Care Produced Fresh Formulation CD19 CAR-T Cell Therapy in Patients with Relapsed or Refractory CD19+ B-cell Acute Lymphocytic Leukemia Ruta Semaskeviciene (Vilnius, Lithuania)	19:55 - 19:55
Time of Infusion Does Not Significantly Impact Outcomes Following CAR T-cell Therapy in Large B-cell Lymphoma	19:55 - 19:55
Novel Salinomycin Analogs Potentiate Anti-CD20 CAR-T and Antibody-dependent Immunotherapy	19:55 - 19:55
Lactobacillus-derived Postbiotics Enhance CAR T Cells Cytotoxicity and <i>in vivo</i> Tumor Control	19:55 - 19:55
Durability of Tisagenlecleucel in Pediatric ALL Is Associated with Post Allo-HSCT Status	19:55 - 19:55

Rakefet Sidlik Muskatel (Petach Tikva, Israel)

Friday, February 13, 2026

Best Abstracts

08:30 - 09:30

Plenary

BA1 - Best Abstracts 1

A Novel CAR-T Cell Therapy Product (Talicabtagene Autoleucel: Tali-cel) Shows Promising Activity in Relapsed/ Refractory B-acute Lymphoblastic-leukemia (R/R B-ALL) Patients: Phase Ib/II Clinical Trial

08:40 - 08:50

Gaurav Narula (Mumbai, India)

Circadian Glucocorticoid Exposure Governs Tumor-intrinsic Antigenicity and Immunotherapeutic Response in Solid Cancers

08:50 - 09:00

Marc Philipp Schauer (Würzburg, Germany)

Implications of Costimulatory Domain Choice: 4-1BB-CAR-T Cells Promote CD19 Uptake-associated Resistance in Hematologic Malignancies

09:00 - 09:10

Updated Results from a Phase I Trial of CD19/CD22 BiCistronic CAR T-cells in Children, Adolescents, and Young Adults with Recurrent or Refractory B-cell ALL

09:10 - 09:20

Decreased Hematologic Toxicity and Infectious Complications in LBCL Patients Receiving CD19 CAR-T in Earlier versus Advanced Treatment Lines

09:20 - 09:30

Physicians Session

08:30 - 09:30

Breakout

PS4 - Clinical Cases

Alexandros Rampotas (London, United Kingdom)

Koray Yalcin (Istanbul, Turkey)

PS4-1

Myeloma clinical case

08:30 - 08:50

Hermann Einsele (Würzburg, Germany)

PS4-2

Solid tumor case | Autoimmune, Lymphoma and Other

08:50 - 09:10

Complete Response in Relapsed/Refractory POEMS Syndrome after ARI0002h, an Academic BCMA-directed CAR-T Cell Therapy: A Case Report

09:10 - 09:10

PS4-3

NK

09:10 - 09:30

Katy Rezvani (Houston, United States)

Nurses Session

08:30 - 09:15

Nurses

NG1 - Opening and Keynote Lecture on CAR T beyond haematological disorders

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NiChonghaile (Dublin, Ireland)

NG1-1

Welcome and Introduction

08:30 - 08:40

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NiChonghaile (Dublin, Ireland)

NG1-2

CAR T beyond haematological disorders

08:40 - 09:15

Raffaella Greco (Milano, Italy)

Nurses Session

09:30 - 10:45

Nurses

NG2 - Exploring CAR T cell Therapy

Erik Aerts (Zürich, Switzerland)

Ruth Clout (Manchester, United Kingdom)

NG2-4	Bridging Therapy and implications in CAR T Erik Aerts (Zürich, Switzerland)	09:30 - 09:50
NG2-3	Symptom Management Ruth Clout (Manchester, United Kingdom)	09:50 - 10:10
NG2-2	Models of care for CAR T programmes Emily John (London, United Kingdom)	10:10 - 10:30
NG2-1	The role of CAR T in Myeloma Monique Minnema (Utrecht, Netherlands)	10:30 - 10:45

Physicians Session

09:45 - 10:45

Plenary

PS5A - Solid tumours

Concetta Quintarelli (Rome, Italy)

Annette Künkele (Berlin, Germany)

PS5A-1	Beyond hematology: CART for pediatric solid tumors Francesca del Bufalo (Rome, Italy)	09:45 - 10:05
PS5A-2	NAP CAR T cells for solid tumors Magnus Essand (Uppsala, Sweden)	10:05 - 10:25
PS5A-3	GPC3 CAR-T cells for patients with solid cancers David H. Steffin (Houston, United States)	10:25 - 10:45

Physicians Session

09:45 - 10:45

Breakout

PS5B - International Session

Raffaella Greco (Milano, Italy)

Alexandros Spyridonidis (Patras, Greece)

PS5B-1	Greece Alexandros Spyridonidis (Patras, Greece)	09:45 - 10:05
PS5B-2	Brazil Vanderson Rocha (São Paulo, Brazil)	10:05 - 10:25
PS5B-3	Russia Michael Maschan (Moscow, Russian Federation)	10:25 - 10:45

Break

10:45 - 11:25

IT

Coffee Break*Industry Theatre*

10:55 - 11:15

IT

IT02 - Industry Theatre / Tech Talk 2

Physicians Session

11:25 - 12:55

Plenary

PS6A - Indications beyond cancer

Raffaella Greco (Milano, Italy)

Ibrahim Yakoub-Agha (Lille, France)

PS6A-1	Profiling patients at risk for CART complications Fabio Ciceri (Milano, Italy)	11:25 - 11:45
PS6A-2	CART in rheumatic autoimmune diseases Dimitrios Mougiakakos (Magdeburg, Germany)	11:45 - 12:05
PS6A-3	Haemophilia Felicitas Thol (Hannover, Germany)	12:05 - 12:25

Physicians Session

11:25 - 12:55

Breakout

PS6B - Manufacturing & Regulatory aspects

Ulrike Köhl (Leipzig, Germany)

Christian Chabannon (Marseille, France)

PS6B-1	To be announced Ulrich Storz (Duesseldorf, Germany)	11:25 - 11:42
PS6B-2	Evidence generation for regulatory decision-making for a next wave of CART Lourens Bloem (Utrecht, Netherlands)	11:42 - 11:59
PS6B-4	Switching from viral to non-viral gene transfer for CAR manufacturing Ulrike Köhl (Leipzig, Germany)	11:59 - 12:16
PS6B-5	Allo CAR T manufacturing Waseem Qasim (London, United Kingdom)	12:16 - 12:33
PS6B-6	Discussion	12:33 - 12:55

Nurses Session

11:25 - 13:00

Nurses

NG3 - Navigating social and care challenges in CAR T Therapy

Michelle Kenyon (London, United Kingdom)

Sara Ubovic (Zürich, Switzerland)

NG3-1	The challenges of CAR T in adolescents & young adults Matteo Amicucci (ROME, Italy)	11:25 - 11:50
NG3-2	Social media - a bonus to CAR T therapy - advantages & challenges Thomas Jezequel (Nantes, France)	11:50 - 12:10
NG3-3	Advanced Care Planning and CAR T therapy Joica Benschp (Rotterdam, Netherlands)	12:10 - 12:35
NG3-4	Advanced Practice Roles in CAR T, opportunities, challenges & future directions Daniel Kisielewski (Stuttgart, Germany)	12:35 - 13:00

Break

12:55 - 13:45

IT

Lunch Break

Satellite Symposium

13:45 - 14:30

Plenary

SS02 - Satellite Symposium by Johnson & Johnson*Nurses Session*

13:45 - 14:30

Nurses

NG4 - Best Abstracts**Time from Onset to Severe ICANS Following CAR-T Therapy: A Retrospective Study to Inform ICE Assessment Frequency**

13:45 - 13:45

Jemma Stewart (Melbourne, Australia)

Ella Weisser (Melbourne, Australia)

Survey on Fertility Management and Outcomes after Cellular Therapies, on behalf of the EBMT Cellular Therapy and Immunobiology Working Party

13:45 - 13:45

Patient-reported Outcomes: Challenges with Cognitive Impairment Post CAR-T Treatment

13:45 - 13:45

Combination of Low Physical Performance and Sarcopenia Is Associated with Inferior Outcomes in CAR T-cell Recipients: Results of a Real-world Pilot Study

13:45 - 13:45

Dermatological Complications in CAR-T Cells Therapy: A New Clinical Challenge for BMT Nurses

13:45 - 13:45

Physicians Session

14:45 - 16:15

Plenary

PS7 - Translational II: CAR T models & mechanisms

Michael Hudecek (Würzburg, Germany)

Sonia Guedan (Barcelona, Spain)

PS7-1

Keynote Lecture

14:45 - 15:15

Michel Sadelain (New York, United States)

PS7-2

Multi-omics Single cell, 3D imaging and resistance in niche

15:15 - 15:35

Zsolt Sebestyen (Utrecht, Netherlands)

PS7-3

Enhancing CAR T efficacy

15:35 - 15:55

Evan Weber (Philadelphia, United States)

PS7-4

Dissection of CAR T cell function in Glioblastoma

15:55 - 16:15

Cécile Alanio (Paris, France)

Nurses Session

14:45 - 16:15

Nurses

NG5 - Survivorship & Outcomes in CAR T

Hilda Mekelenkamp (Leiden, Netherlands)

Mairéad NiChonghaile (Dublin, Ireland)

NG5-1

Case presentation

14:45 - 14:55

NG5-2

Nurses experiences

14:55 - 15:10

Sara Ubovic (Zürich, Switzerland)

NG5-3

QoL in patients after CAR T

15:10 - 15:25

Mercedes Montoro-Lorite (Barcelona, Spain)

NG5-4

Survivorship, the road to recovery

15:25 - 15:40

Michelle Kenyon (London, United Kingdom)

NG5-5

Patient voice

15:40 - 15:50

NG5-6	Discussion	15:50 - 16:15
<i>Break</i>		
16:15 - 16:50		IT
Coffee Break		
<i>Industry Theatre</i>		
16:25 - 16:45		IT
IT03 - Industry Theatre / Tech Talk 3		
<i>Satellite Symposium</i>		
16:50 - 17:35		Plenary
SS03 - Satellite Symposium by Gilead & Kite		
<i>Nurses Session</i>		
16:50 - 17:30		Nurses
NG6 - Keynote Lecture on Patient & Stakeholder Engagement- a true collaborative approach to care		
Hilda Mekelenkamp (Leiden, Netherlands)		
Mairéad NiChonghaile (Dublin, Ireland)		
NG6-1	Patient & Stakeholder Engagement- a true collaborative approach to care	16:50 - 17:20
	Natacha Bolaños (Madrid, Spain)	
NG6-2	Discussion	17:20 - 17:30
<i>Nurses Session</i>		
17:30 - 17:45		Nurses
NG7 - Closing remarks		
Mairéad NiChonghaile (Dublin, Ireland)		
Hilda Mekelenkamp (Leiden, Netherlands)		
NG7-1	Closing remarks	17:30 - 17:45
<i>Keynote</i>		
17:45 - 18:15		Plenary
KN3 - Keynote Lecture 3		
Ulrike Köhl (Leipzig, Germany)		
KN3	Keynote Lecture	17:45 - 18:15
	Marcela Maus (Boston, United States)	
<i>Keynote</i>		
18:25 - 19:10		Plenary
KN4 - Keynote Roundtable		
	Keynote Roundtable	18:25 - 18:25
	Marcela Maus (Boston, United States)	
	Carl June (Philadelphia, United States)	
	Michel Sadelain (New York, United States)	
	Katy Rezvani (Houston, United States)	
	Dirk Busch (Munich, Germany)	

Saturday, February 14, 2026

Physicians Session

08:30 - 10:00

Plenary

PS9A - Lymphomas and CLL

Stephan Mielke (Stockholm, Sweden)

Anna Sureda (Barcelona, Spain)

PS9A-1	CLL Maria Luisa Schubert (Heidelberg, Germany)	08:30 - 08:50
PS9A-2	Bispecifics vs CART Catherine Thieblemont (Paris, France)	08:50 - 09:10
PS9A-3	NHL Tom van Meerten (Groningen, Netherlands)	09:10 - 09:30
PS9A-4	T-NHL & HL Javier Briones (Barcelona, Spain)	09:30 - 09:50
PS9A-5	Discussion	09:50 - 10:00

Best Abstracts

08:30 - 10:00

Breakout

BA2 - Best abstracts 2

Endothelial Dysfunction and Astrocyte Reactivity Drive ICANS in CAR-T Cell Therapy Rita El Khoury (Milan, Italy)	08:30 - 08:40
An Open CAR-T Single-cell Atlas to Enable In-depth Characterization and Rational Engineering of CAR-T Products Juan Roberto Rodriguez-Madoz (Pamplona, Spain)	08:40 - 08:50
CD19/CD84 IF-BETTER Dual CAR T Cells Overcome Antigen-low Relapse and Outperform CART19 in CD19-low B-ALL Models Ane Altuna (Barcelona, Spain)	08:50 - 09:00
Early Intervention for Cytokine Release Syndrome after CAR T-cell Therapy Is Associated with Increased Risk of Cytopenias and Infections in Patients with Large B-cell Lymphoma	09:00 - 09:10
Successful Treatment of Patients with Relapsed/Refractory Systemic Light Chain Amyloidosis with the Novel MDC-CAR-BCMA001 Kiavasch Mohammad Nejad Farid (Heidelberg, Germany)	09:10 - 09:20
Cellular Kinetics, Efficacy, and Safety of Zamtocabtagene Autoleucel, a Tandem CD20-CD19 Directed CAR-T Cell Therapy, vs R-GemOx in Patients with Relapsed/Refractory LBCL (DALY 2-EU Study)	09:20 - 09:30

Best Abstracts

10:15 - 11:00

Plenary

BA3 - Best abstracts 3

Targeting ENTPD3 with CAR Tregs for Antigen-specific Immunotherapy in Type 1 Diabetes Tom Pieper (Hannover, Germany)	10:15 - 10:25
Universal Gene-edited CD45CAR T-cells for AML Jenny Yeung (London, United Kingdom)	10:25 - 10:35

	Rapcabbitagene Autoleucel (YTB323) for Patients with First Line High-risk Large B-cell Lymphoma (1L HR LBCL): Phase 2 Interim Results	10:35 - 10:45
	A Longitudinal Single-cell Atlas to Predict Outcome and Toxicity after BCMA-directed CAR T Cell Therapy in Multiple Myeloma	10:45 - 10:55
<i>Break</i> 11:00 - 11:40		IT
Coffee Break		
<i>Industry Theatre</i> 11:10 - 11:30		IT
IT04 - Industry Theatre / Tech Talk 4		
<i>Physicians Session</i> 11:40 - 12:40		Plenary
PS8 - Myeloma		
Hermann Einsele (Würzburg, Germany) Sonja Zweegman (Amsterdam, Netherlands)		
PS8-1	Bispecifics vs CART Paula Rodríguez-Otero (Pamplona, Spain)	11:40 - 12:00
PS8-2	Target finding for MM Arun Wiita (San Francisco, United States)	12:00 - 12:20
PS8-3	Access to therapy in MM Mohamad Mohty (Paris, France)	12:20 - 12:40
<i>Physicians Session</i> 11:40 - 12:40		Breakout
PS9B - Building Alignment in CAR-T Data Collection: From Delphi Consensus to Sustainable Collaboration		
Carmen Sanges (Würzburg, Germany)		
PS9B-1	Overview, T2EVOLVE-GoCART harmonisation efforts, objectives of session, introduction of working group Carmen Sanges (Würzburg, Germany)	11:40 - 11:45
PSB9-2	From Consensus to Implementation: Results of the Delphi Survey Jürgen Kuball (Utrecht, Netherlands)	11:45 - 11:55
PS9B-3	EBMT Registry Perspective	11:55 - 12:05
PS9B-4	National Experience: Austrian OMOP Integration	12:05 - 12:15
PS9B-5	CERTAINTY Project and Future Outlook Kristin Reiche (Leipzig, Germany)	12:15 - 12:25
PSB9-6	Panel discussion, Q&A and closing remarks Carmen Sanges (Würzburg, Germany) Jürgen Kuball (Utrecht, Netherlands) Kristin Reiche (Leipzig, Germany)	12:25 - 12:40
<i>Physicians Session</i> 12:55 - 13:50		Breakout
CL - Closing Ceremony, Best abstracts & Awards		
	CART Cells Targeting the Immunosuppressive Bone-Marrow	12:55 - 13:05

Microenvironment to Successfully Combat Resistance in Multiple Myeloma

Jennifer Meyer Feigin (Rochester, United States)

Direct in vivo CAR T Cell Engineering via a T-cell-Tropic AAV-transposon Platform

13:05 - 13:15

Mobina Ostadiasrami (Würzburg, Germany)

HYPO-CAR-T: Impact of Early Corticosteroid Minimization on Relapse and Neurotoxicity across a Multicenter Real-world Cohort

13:15 - 13:25

Seroprotection against Vaccine-preventable Infections Is Inferior at Baseline and Remains Diminished in BCMA- Compared to CD19-CAR T Recipients

13:25 - 13:35